The nanoparticles thus showed the magnetic-targeted NIR-II PTT treatment, which could be combined with anti-PD-1-mediated immunotherapy to inhibit the tumor recurrence and metastasis of 4T1 tumor-bearing-mouse models. This evidence concerns the gene PDCD1 and neoplasm.